人人妻人人澡人人爽人人DVD,安徽妇搡BBBB搡BBBB小说,丰满岳乱妇一区二区三区,少妇高潮灌满白浆毛片免费看

中文
關(guān)于我們
主營業(yè)務(wù)
技術(shù)平臺
學(xué)術(shù)交流
新聞中心
加入我們
主營業(yè)務(wù)
表單填寫
*姓名
*電話
*郵箱
*公司
*留言信息
熙寧小課-第159期 | FDA, OECD及CFDA (NMPA) GLP法規(guī)比較——系列10 項(xiàng)目實(shí)施
發(fā)布作者:熙寧生物發(fā)布時間:2024-11-08


CFDA


· 第八章 第二十六條

每個試驗(yàn)均應(yīng)當(dāng)有名稱或者代號,并在研究相關(guān)的文件資料及試驗(yàn)記錄中統(tǒng)一使用該名稱或者代號。試驗(yàn)中所采集的各種樣本均應(yīng)當(dāng)標(biāo)明該名稱或者代號、樣本編號和采集日期。


OECD


· Section II

8.3.1. A unique identification should be given to each study. All items concerning this study should carry this identification. Specimens from the study should be identified to confirm their origin. Such identification should enable traceability, as appropriate for the specimen and study.


FDA


-



· 

OECD與CFDA均要求一項(xiàng)研究應(yīng)有一個唯一代號,研究的相關(guān)文件和記錄以及產(chǎn)生的樣本均應(yīng)使用該代號,以便于識別和追溯。

·  

FDA則無該要求。



CFDA


· 第八章 第三十條 

參加研究的工作人員應(yīng)當(dāng)嚴(yán)格執(zhí)行試驗(yàn)方案和相應(yīng)的標(biāo)準(zhǔn)操作規(guī)程,記錄試驗(yàn)產(chǎn)生的所有數(shù)據(jù),并做到及時、直接、準(zhǔn)確、清楚和不易消除,同時需注明記錄日期、記錄者簽名。


OECD


· 58.130

(a) The nonclinical laboratory study shall be conducted in accordance with the protocol.

(e) All data generated during the conduct of a nonclinical laboratory study, except those that are generated by automated data collection systems, shall be recorded directly, promptly, and legibly in ink. All data entries shall be dated on the date of entry and signed or initialed by the person entering the data.


FDA


· Section II

8.3.2. The study should be conducted in accordance with the study plan.

8.3.3. All data generated during the conduct of the study should be recorded directly, promptly, accurately, and legibly by the individual entering the data. These entries should be signed or initialled and dated.



· 

要求一致。                                                                 




CFDA


· 第八章 第三十條 

記錄的數(shù)據(jù)需要修改時,應(yīng)當(dāng)保持原記錄清楚可辨,并注明修改的理由及修改日期、修改者簽名。


OECD


· 58.130

(e) Any change in entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change.


FDA


· Section II

8.3.4. Any change in the raw data should be made so as not to obscure the previous entry, should indicate the reason for change and should be dated and signed or initialled by the individual making the change.



· 

要求一致。                                                                 




CFDA


· 第八章 第三十條 

電子數(shù)據(jù)的生成、修改應(yīng)當(dāng)符合以上要求。


OECD


· 58.130

(e) In automated data collection systems, the individual responsible for direct data input shall be identified at the time of data input. Any change in automated data entries shall be made so as not to obscure the original entry, shall indicate the reason for change, shall be dated, and the responsible individual shall be identified.


FDA


· Section II

8.3.5. Data generated as a direct computer input should be identified at the time of data input by the individual(s) responsible for direct data entries. Computerised system design should always provide for the retention of full audit trails to show all changes to the data without obscuring the original data. It should be possible to associate all changes to data with the persons having made those changes, for example, by use of timed and dated (electronic) signatures. Reason for changes should be given.



· 

要求一致。                                                                 

· 

CFDA中一句帶過,而FDA與OECD給出詳細(xì)描述。電子數(shù)據(jù)在產(chǎn)生的當(dāng)時就應(yīng)該能夠可追溯至責(zé)任人。電子數(shù)據(jù)修改的要求也是與紙質(zhì)記錄的修改要求一致。OECD中提到審計追蹤和電子簽名,而FDA中并未出現(xiàn)這樣的名詞。CFDA中雖沒有出現(xiàn)審計追蹤和電子簽名,但是在定義中是有的。                                                       




CFDA


-

OECD

-

FDA

· 58.130

(b) The test systems shall be monitored in conformity with the protocol.

(c) Specimens shall be identified by test system, study, nature, and date of collection. This information shall be located on the specimen container or shall accompany the specimen in a manner that precludes error in the recording and storage of data.

(d) Records of gross findings for a specimen from postmortem observations should be available to a pathologist when examining that specimen histopathologically.


CFDA

· 第八章 第三十一條  

進(jìn)行病理學(xué)同行評議工作時,同行評議的計劃、管理、記錄和報告應(yīng)當(dāng)符合以下要求:

(一)病理學(xué)同行評議工作應(yīng)當(dāng)在試驗(yàn)方案或者試驗(yàn)方案變更中詳細(xì)描述;

(二)病理學(xué)同行評議的過程,以及復(fù)查的標(biāo)本和文件應(yīng)當(dāng)詳細(xì)記錄并可追溯;

(三)制定同行評議病理學(xué)家和專題病理學(xué)家意見分歧時的處理程序;

(四)同行評議后的結(jié)果與專題病理學(xué)家的診斷結(jié)果有重要變化時,應(yīng)當(dāng)在總結(jié)報告中論述說明;

(五)同行評議完成后由同行評議病理學(xué)家出具同行評議聲明并簽字注明日期;

(六)總結(jié)報告中應(yīng)當(dāng)注明同行評議病理學(xué)家的姓名、資質(zhì)和單位。

OECD

-

FDA

-


歡迎各位同行進(jìn)行勘誤及指出不足之處。



參考文獻(xiàn):

[1] US FDA Good Laboratory Practice Regulations 21 CFR 58,effective June 20, 1979 and subsequent amendments

[2] OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted November 26th, 1997 by decision of the OECD Council [C (97)186/Final]

[3] 國家食品藥品監(jiān)督管理總局,藥物非臨床研究質(zhì)量管理規(guī)范,2017年9月1日生效


專屬客服
免費(fèi)通話
表單填寫
回到頂部
久久99国产精品1区二区 | 夜夜爽妓女77777免费观看院 | 国产AV一区二区三区 | 大象传媒色情永久免费版 | 免费国产传媒av在线观看 | 亚洲AV无码乱码棈品熟妇 | 欧美精品乱码99久久影院 | 国产一级特黄a高潮片 | 精品国产Av无码久久久伦古装 | 四川少妇BBBBBB爽爽爽欧美 | 国产精品内射婷婷一级二 | 国产亚洲精品无码在线观看 | 午夜精品视频在线观看 | 91精品人妻中文字幕色欲 | 国产欧美一区二区精品性色超碰 | 欧美一交一乱一交免费看 | 欧美一区少妇喷水人妻 | 精品无码人妻一区二区媚黑 | 中出受孕中文字幕在线 | 亚洲精品久久久久久久玉蒲团 | 无码人妻aV一区二区三区色欲 | 91精品人妻一区二区三区蜜桃丨 | 精品无码人妻一区二区免费蜜桃 | 成人性爱免费网站 | 亚洲AV无码在线播放 | 亚洲の无码国产の无码步美 | 粉嫩娇妻无码视频在线观看 | 极品少妇勾引在线观看 | 韩国无码成人三区在线观看 | 蜜桃av鲁一鲁一鲁一鲁 | 亚洲综合免费视频 | 西西4444www无码国模吧 | 自慰喷水在线观看 | 国产亚洲精品久久久久久豆腐 | 亚洲裸体漫画在线观看 | 在线播放不卡AV | 欧美成人午夜精品三级理论 | 成人免费视频 国产免费麻豆 | 国产精品妖精久久人妻嫩 | 99成人兔费视频在线播放 | 中文无码在线视频 |